Marshall Wace North America L.P. lowered its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 65.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 101,883 shares of the medical instruments supplier’s stock after selling 191,712 shares during the period. Marshall Wace North America L.P.’s holdings in DENTSPLY SIRONA were worth $6,622,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BB&T Securities LLC boosted its position in DENTSPLY SIRONA by 59.2% in the second quarter. BB&T Securities LLC now owns 7,056 shares of the medical instruments supplier’s stock valued at $457,000 after buying an additional 2,623 shares during the last quarter. KBC Group NV raised its stake in DENTSPLY SIRONA by 18.3% in the second quarter. KBC Group NV now owns 23,055 shares of the medical instruments supplier’s stock valued at $1,495,000 after buying an additional 3,573 shares during the period. Cidel Asset Management Inc. raised its stake in DENTSPLY SIRONA by 1.5% in the second quarter. Cidel Asset Management Inc. now owns 326,349 shares of the medical instruments supplier’s stock valued at $21,160,000 after buying an additional 4,913 shares during the period. Bridgewater Wealth & Financial Management LLC bought a new stake in DENTSPLY SIRONA during the second quarter valued at about $214,000. Finally, Ballentine Partners LLC bought a new stake in DENTSPLY SIRONA during the second quarter valued at about $203,000. Hedge funds and other institutional investors own 93.97% of the company’s stock.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) opened at 54.80 on Monday. The stock’s 50 day moving average price is $59.93 and its 200-day moving average price is $62.08. The firm’s market capitalization is $12.58 billion. DENTSPLY SIRONA Inc. has a 52 week low of $52.53 and a 52 week high of $65.68.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. The company had revenue of $992.70 million during the quarter, compared to analyst estimates of $1 billion. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the business posted $0.76 earnings per share. Equities analysts predict that DENTSPLY SIRONA Inc. will post $2.68 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 29th will be given a $0.0875 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.35 annualized dividend and a yield of 0.64%. DENTSPLY SIRONA’s dividend payout ratio is currently -10.09%.

COPYRIGHT VIOLATION WARNING: “Marshall Wace North America L.P. Sells 191,712 Shares of DENTSPLY SIRONA Inc. (XRAY)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/28/marshall-wace-north-america-l-p-sells-191712-shares-of-dentsply-sirona-inc-xray.html.

Several research firms have recently issued reports on XRAY. HC Wainwright reissued a “buy” rating and set a $68.00 target price (down from $74.00) on shares of DENTSPLY SIRONA in a report on Monday, August 14th. Credit Suisse Group reissued an “outperform” rating and set a $75.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a report on Thursday, July 13th. BidaskClub raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, June 30th. TheStreet lowered DENTSPLY SIRONA from a “b” rating to a “c+” rating in a report on Wednesday, August 9th. Finally, Morgan Stanley increased their target price on DENTSPLY SIRONA from $66.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. DENTSPLY SIRONA presently has a consensus rating of “Hold” and an average price target of $66.08.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.